Ilaris ® (Canakinumab)
UnitedHealthcare Community Plan of Indiana revised its Ilaris (canakinumab) medical benefit drug policy for Indiana Medicaid members, effective 2026-12-01. Coverage is now stated for CAPS (including FCAS and MWS), TRAPS, HIDS/MKD, FMF (after colchicine failure, contraindication or intolerance), and active Still's disease (AOSD and SJIA), each with initial and continuation criteria and authorization periods of no more than 12 months, and the policy adds a list of applicable ICD-10 diagnosis codes; the Indiana-exclusion language was also removed.